# CORRIGENDUM

# Factors Associated with Adherence to Immunosuppressive Therapy and Barriers in Asian Kidney Transplant Recipients [Corrigendum]

Ganjali R, Sabbagh MG, Nazemiyan F, et al. The authors apologize for this error. Immunotargets Ther. 2019;8:53-62.

The authors have advised that Table 2 on page 57 is incorrect. The correct table is shown below.

# Table 2 Immunosuppression Non-Adherence of the Study Sample Measured Based on the BAASIS© Instrument (n=133)

Adherence Behavior in Previous 4 Weeks		N (%) (n=133)	Total N (%)
I. Not taking a dose of immunosuppressive medications in the past 4 weeks	Once	26 (19.5)	40 (30)
	More than once	14 (10.6)	
2. Not taking multiple consecutive doses of immunosuppressive medications in the past 4 weeks	Once	14 (10.5)	22 (16.6)
	More than once	8 (6.1)	
3. Taking immunosuppressive medications at least two hours earlier or later than the time indicated on the dosing administration schedule in the past 4 weeks	Once	54 (40.6)	3 (86.7)
	More than once	59 (45.9)	
4. Reducing the dosage of immunosuppressive medications on your own initiative in the past 4 weeks	Once	14 (10.5)	21 (15.8)
	More than once	7 (5.3)	
Sum	Once	108 (81.2)	
	More than once	88 (66.17)	
5. Self-rated score on correct administration of © immunosuppressive medications (min: 0, max: 10) <sup>a</sup>	Non-adherent	7.72 (±1.98)	

Notes: Patients were non-adherent patients if they answered yes to the 4 first BAASIS© questions. <sup>a</sup>Question 5 was a Visual Analogue Scale (0–10) with higher scores indicating better adherence. The absolute value was taken and a mean score over all patients was calculated (±SD). BAASIS© University of Basel, Leuven-Basel Research Group, Institute of Nursing Science, Department Public Health, University of Basel, Switzerland, 2005. Permission & conditions to use the BAASIS© can be obtained from: http://baasis.nursing.unibas.ch/or sabina.degeest@unibas.ch.

#### ImmunoTargets and Therapy

# **Dove**press

# Publish your work in this journal

ImmunoTargets and Therapy is an international, peer-reviewed open access journal focusing on the immunological basis of diseases, potential targets for immune based therapy and treatment protocols employed to improve patient management. Basic immunology and physiology of the immune system in health, and disease will be also covered. In addition, the journal will focus on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/immunotargets-and-therapy-journal



ImmunoTargets and Therapy 2020:9 141

© 2020 Ganjali et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

141